Increasing Catecholamine Secretion Through NPY in Pheochromocytomas With False-Negative 123 I-MIBG Scintigraphy
- PMID: 38546331
- DOI: 10.1097/RLU.0000000000005139
Increasing Catecholamine Secretion Through NPY in Pheochromocytomas With False-Negative 123 I-MIBG Scintigraphy
Abstract
Introduction: 123 I-MIBG has been well established as a functional imaging tool, and 131 I-MIBG therapy is being considered for catecholamine-secreting tumors. Tumors with the characteristics of a noradrenergic biochemical phenotype, small, malignant, metastatic, extra-adrenal, bilateral, and hereditary, especially SDHx -related tumors, are reported to correlate with reduced MIBG uptake. However, the potential molecular mechanisms influencing MIBG uptake have been poorly studied.
Patients and methods: To identify critical genes that may enhance MIBG accumulation in pheochromocytomas (PCCs), we performed RNA-seq analyses for 16 operated patients with PCCs (6 MIBG-negative and 10 MIBG-positive) combined with RT-qPCR for 27 PCCs (5 MIBG-negative and 22 MIBG-positive) and examined primary cultures of the surgical tissues.
Results: In the present study, 6 adrenal nodules of 66 nodules surgically removed from 63 patients with PCCs (9%) were MIBG negative. MIBG, a guanethidine analog of norepinephrine, can enter chromaffin cells through active uptake via the cellular membrane, be deposited in chromaffin granules, and be released via Ca 2+ -triggered exocytosis from adrenal chromaffin cells. When we compared expression of several catecholamine biosynthesis and secretion-associated genes between MIBG-negative and MIBG-positive tumors using transcriptome analyses, we found that neuropeptide Y, which is contained in chromaffin granules, was significantly increased in MIBG-negative tumors. NPY stimulated norepinephrine secretion dose-dependently in primary cell culture derived from MIBG-positive PCC. In our study, MIBG-negative PCCs were all norepinephrine-hypersecreting tumors.
Conclusions: These data indicate that NPY upregulation in PCCs may stimulate chromaffin granule catecholamine secretion, which is associated with false-negative 123 I-MIBG scintigraphy.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest and sources of funding: The authors have declared no conflicts of interest. This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.
Similar articles
-
Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.J Nucl Med. 2015 Jun;56(6):839-46. doi: 10.2967/jnumed.115.154815. Epub 2015 Apr 16. J Nucl Med. 2015. PMID: 25883126
-
Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging.Q J Nucl Med Mol Imaging. 2008 Dec;52(4):419-29. Q J Nucl Med Mol Imaging. 2008. PMID: 19088695 Review.
-
Diagnostic accuracy of radionuclide imaging using 131I nor-cholesterol or meta-iodobenzylguanidine in patients with hypersecreting or non-hypersecreting adrenal tumours.Nucl Med Commun. 2002 Oct;23(10):951-60. doi: 10.1097/00006231-200210000-00004. Nucl Med Commun. 2002. PMID: 12352593
-
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.J Clin Endocrinol Metab. 2001 Feb;86(2):685-93. doi: 10.1210/jcem.86.2.7238. J Clin Endocrinol Metab. 2001. PMID: 11158032
-
Imaging of catecholamine-secreting tumours: uses of MIBG in diagnosis and treatment.Baillieres Clin Endocrinol Metab. 1993 Apr;7(2):491-507. doi: 10.1016/s0950-351x(05)80185-5. Baillieres Clin Endocrinol Metab. 1993. PMID: 8489488 Review.
References
-
- DeLellis RA; International Agency for Research on C. Pathology and Genetics of Tumours of Endocrine Organs . Lyon, France: IARC Press; 2004.
-
- Tan TH, Hussein Z, Saad FF, et al. Diagnostic performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma. Nucl Med Mol Imaging . 2015;49:143–151.
-
- Chang CA, Pattison DA, Tothill RW, et al. (68)Ga-DOTATATE and (18)F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging . 2016;16:22.
-
- Jaiswal SK, Sarathi V, Malhotra G, et al. The utility of 68 Ga-DOTATATE PET/CT in localizing primary/metastatic pheochromocytoma and paraganglioma: Asian Indian experience. Indian J Endocrinol Metab . 2021;25:410–417.
-
- Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab . 2014;99:1915–1942.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous